Excitatory effects of hypocretin-1 (orexin-A) in the trigeminal motor nucleus are reversed by NMDA antagonism

Journal of Neurophysiology

Volumn 89, Issue 5, 2003, Pages 2591-2600

  Peever, John H ^a   Lai, Yuan Yang ^b   Siegel, Jerome M ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; GLUTAMIC ACID; LIGAND; METHYSERGIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPEPTIDE; OREXIN A; OREXIN B; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; BRAIN REGION; CAT; CATAPLEXY; CONTROLLED STUDY; DECEREBRATION; DOSE RESPONSE; DRUG EFFECT; FEMALE; HYPOGLOSSAL NUCLEUS; HYPOTHALAMUS; MASSETER MUSCLE; MICROINJECTION; MOTONEURON NUCLEUS; MOTOR CONTROL; MUSCLE CONTRACTION; MUSCLE TONE; NARCOLEPSY; NERVE CELL STIMULATION; NERVE PROJECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRIGEMINAL NUCLEUS;

2-AMINO-5-PHOSPHONOVALERATE; ANIMALS; CARRIER PROTEINS; CATS; DECEREBRATE STATE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRODES, IMPLANTED; ELECTROMYOGRAPHY; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FUNCTIONAL LATERALITY; HYPOGLOSSAL NERVE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICROINJECTIONS; MOTOR NEURONS; MUSCLE TONUS; MUSCLE, SKELETAL; NEUROPEPTIDES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, NEUROPEPTIDE; SEROTONIN ANTAGONISTS; TRIGEMINAL NUCLEI;

EID: 0037509894     PISSN: 00223077     EISSN: None     Source Type: Journal    
DOI: 10.1152/jn.00968.2002     Document Type: Article

References (44)

1. Abrahamson EE, Leak RK, and Moore RY. The suprachiasmatic nucleus projects to posterior hypothalamic arousal systems. Neuroreport 12: 435-440, 2001.
2. Bae YC, Nakamura T, Ihn HJ, Choi MH, Yoshida A, Moritani M, Honma S, and Shigenaga Y. Distribution pattern of inhibitory and excitatory synapses in the dendritic tree of single masseter alpha-motoneurones in the cat. J Comp Neurol 414: 454-468, 1999.
3. Berman AL. The Brain Stem of the Cat. Madison, WI: University of Wisconsin, 1968.
4. Burlet S, Tyler CJ, and Leonard CS. Direct and indirect excitation of laterodorsal tegmental neurons by hypocretin/orexin peptides: implications for wakefulness and narcolepsy. J Neurosci 22: 2862-2872, 2002.
5. Chemelli RM, Willie JT, Sinton C, Elmquist J, Scammell T, Lee C, Richardson J, Williams S, Xiong Y, Kisanuki Y, Fitch T, Nakazato M, Hammer R, Saper C, and Yanagisawa M. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98: 437-451, 1999.
6. De Lecea L, Kilduff T, Peyron C, Gao XB, Foye PE, Danielson PE, Fukahara C, Battenberg ELF, Gautvik VT, Barlett FS, Frankel WN, van den Pol AN, Bloom F, Gautvik KM, and Sutcliffe JG. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Nat Acad Sci USA 95: 322-327, 1998.
7. Eggermann E, Serafin M, Bayer L, Machard D, Saint-Mleux B, Jones BE, and Muhlethaler M. Orexins/hypocretins excite basal forebrain cholinergic neurons. Neuroscience 108: 177-181, 2001.
8. Estabrooke IV, McCarthy MT, Ko E, Chou TC, Chemelli RM, Yanagisawa M, Saper CB, and Scammell TE. Fos expression in orexin neurons varies with behavioral state. J Neurosci 21: 1656-1662, 2001.
9. Fung SJ, Yamuy J, Sampogna S, Morales FR, and Chase MH. Hypocretin (orexin) input to trigeminal and hypoglossal motoneurons in the cat: a double-labeling immunohistochemical study. Brain Res 903: 257-262, 2001.
10. Guilleminault C. Cataplexy. In: Narcolepsy, edited by Guilleminault C, Dement WC, and Passouant P. New York: Spectrum, 1976, p. 125-143.
11. Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, Benham CD, Taylor SG, Routledge C, Hemmati P, Munton RP, Ashmeade TE, Shah AS, Hatcher JP, Hatcher PD, Jones DN, Smith MI, Piper DC, Hunter AJ, Porter RA, and Upton N. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Nat Acad Sci USA 96: 10911-10916, 1999.
12. Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, Sugiyama F, Yagami K, Goto K, Yanagisawa M, and Sakurai T. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30: 345-354, 2001.
13. Horner RL. Motor control of the pharyngeal musculature and implications for the pathogenesis of obstructive sleep apnea. Sleep 19: 827-853, 1996.
14. Ivanov A and Aston-Jones G. Hypocretin/orexin depolarizes and decreases potassium conductance in locus coeruleus neurons. Neuroreport 11: 1755-1758, 2000.
15. John J, Wu, M.-F, Kodama T, and Siegel JM. Hypocretin-1 (orexin-A) produced changes in glutamate and GABA release: an in vivo microdialysis study. Sleep 24: A20, 2001.
16. John J, Wu M-F, and Siegel JM. Hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res Online 3: 23-28, 2000.
17. Kiyashchenko LI, Mileykovskiy BY, Lai YY, and Siegel JM. Increased and decreased muscle tone with orexin (hypocretin) microinjections in the locus coeruleus and pontine inhibitory area. J Neurophysiol 85: 2008-2016, 2001.
18. Kiyashchenko LI, Mileykovskiy BY, Maidment NT, Lam HA, Wu, M.-F, John J, Peever JH, and Siegel JM. Hypocretin-1/Orexin-A release across the sleep-wakefulness cycle. J Neurosci 22: 5282-5286, 2002.
19. Kodama T and Kimura M. Arousal effects of orexin-A correlate with GLU release from the locus coeruleus in rats. Peptides 23: 1673-1679, 2002.
20. Kubin L, Tojima H, Davies RO, and Pack AI. Serotonergic excitatory drive to hypoglossal motoneurons in the decerebrate cat. Neurosci Lett 139: 243-248, 1992.
21. Kubin L, Tojima H, Reignier C, Pack AI, and Davies RO. Interaction of serotonergic excitatory drive to hypoglossal motoneurons with carbachol-induced, REM sleep-like atonia. Sleep 19: 187-195, 1996.
22. Lai YY and Siegel JM. Medullary regions mediating atonia. J Neurosci 8: 4790-4796, 1988.
23. Lai YY and Siegel JM. Ponto-medullary glutamate receptors mediating locomotion and muscle tone suppression. J Neurosci 11: 2931-2937, 1991.
24. Lai YY, Strahlendorf HK, Fung SJ, and Barnes CD. The actions of two monoamines on spinal motoneurons from stimulation of the locus coeruleus in the cat. Brain Res 484: 268-272, 1989.
25. Lin L, Faraco J, Kadotani H, Rogers W, Lin X, Qui X, de Jong P, Nishino S, and Mignot E. The REM sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor gene. Cell 98: 365-376, 1999.
26. Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M, and Elmquist JK. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 435: 6-25, 2001.
27. Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M, and Goto K. Distribution of orexin neurons in the adult rat brain. Brain Res 827: 243-260, 1999.
28. Nishino S, Ripley B, Overeem S, Nevsimalova S, Lammers GJ, Vankova J, Okun M, Rogers W, Brooks S, and Mignot E. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 50: 381-388, 2001.
29. Okabe S and Kubin L. Role of 5HT1 receptors in the control of hypoglossal motoneurons in vivo. Sleep 19: S150-S153, 1996.
30. Pedroarena C, Castillo P, Chase MH, and Morales FR. The control of jaw-opener motoneurons during active sleep. Brain Res 653: 31-38, 1994.
31. Peever JH, Lai YY, and Siegel JM. Excitatory effects of hypocretin-1 in the trigeminal motor nucleus are reversed by glutamate antagonists. Sleep 25: A9-10, 2002.
32. Peyron C, Tighe DK, van den Pol AN, De Lecea L, Heller HC, Sutcliffe JG, and Kilduff TS. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18: 9996-10015, 1998.
33. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, Kucherlapati M, Fan J, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino S, and Mignot EA. mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nature Med 6: 991-997, 2000.
34. Ribeiro-do-Valle LE, Metzler CW, and Jacobs BL. Facilitation of masseter EMG and masseteric (jaw-closure) reflex by serotonin in behaving cats. Brain Res 550: 197-204, 1991.
35. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, and Yanagisawa M. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92: 573-585, 1998.
36. Siegel JM. Narcolepsy: a key role for hypocretins (orexins). Cell 98: 409-412, 1999.
37. Soja PJ, Finch DM, and Chase MH. Effect of inhibitory amino acid antagonists on masseteric reflex suppression during active sleep. Exp Neurol 96: 178-193, 1987.
38. Sutcliffe JG and De Lecea L. Novel neurotransmitters for sleep and energy homeostasis. Results Probl Cell Differ 26: 239-255, 1999.
39. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford M, and Siegel JM. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27: 469-474, 2000.
40. van den Pol AN. Hypothalamic hypocretin (orexin): robust innervation of the spinal cord. J Neurosci 19: 3171-3182, 1999.
41. van den Pol AN, Gao XB, Obrietan K, Kilduff TS, and Belousov AB. Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin. J Neurosci 18: 7962-7971, 1998.
42. Volgin DV, Saghir M, and Kubin L. Developmental changes in the orexin 2 receptor mRNA in hypoglossal motoneurons. Neuroreport 13: 433-436, 2002.
43. Wu M-F, Gulyani S, Yao E, Mignot E, Phan B, and Siegel JM. Locus coeruleus neurons: cessation of activity during cataplexy. Neuroscience 91: 1389-1399, 1999.
44. Wu M-F, John J, Maidment NT, Lam HA, and Siegel JM. Hypocretin/orexin release in normal and narcoleptic dogs: comparison of the effects of food deprivation, eating, sleep deprivation and movement. Am J Physiol. Regulatory Integrative Comp Physiol 283: R1079-R1086, 2002.